Hepatomegaly Clinical Trial
Official title:
Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus Attending Assiut University Children Hospital
Verified date | September 2018 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To assess the prevalence of hepatomegaly in children and adolescents with type 1 diabetes mellitus, and to find out it᾿s underlying etiology.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | January 1, 2020 |
Est. primary completion date | January 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 18 Years |
Eligibility |
Inclusion Criteria: - Patients with type 1 Diabetes mellitus diagnosed according to the diagnostic criteria of the American Diabetes Association 2011. Exclusion Criteria: - 1-Patients with type 2 diabetes mellitus 2-Patients with secondary diabetes 3-Patients with type 1 diabetes mellitus with other system affection rather than hepatic affection like ( Central nervous system, Respiratory, Renal, Cardiovascular). 4- Syndromic children. 5-Patients known to have liver disease prior to diagnosis of diabetes. |
Country | Name | City | State |
---|---|---|---|
Egypt | Assiut children hospital | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of Hepatomegaly in children and adolescents | the prevalence of different causes of hepatomegaly with type 1 diabetes mellitus . | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
Recruiting |
NCT03801434 -
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
|
Phase 2 | |
Terminated |
NCT02421354 -
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
|
Phase 2 | |
Active, not recruiting |
NCT03499808 -
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
|
Phase 2 | |
Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Withdrawn |
NCT01331642 -
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
|
||
Withdrawn |
NCT02298634 -
Biomarker for Farber Disease (BioFarber)
|
||
Withdrawn |
NCT02298699 -
Biomarker for Sly Disease (MPS VII) (BioSly)
|
||
Active, not recruiting |
NCT00771888 -
Open-Label Extension of LOCKCYST Trial
|
Phase 2/Phase 3 |